Journals / Şişli Etfal Hastanesi Tıp Bülteni / 2014 / Cilt: 48 - Sayı: 4

Portopulmonary hypertension

Portopulmoner Hipertansiyon

Pages
257–263
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Liver transplantation can be done successfully to those who responds the vasodilatator therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Portopulmonary hypertension Portopulmonary hypertension is one of the rare pulmonary complications of portal hypertension.
📊
Key Findings & Data:Portopulmonary hypertension, is the right ventricular dysfunction caused by increased pulmonary artery pressure which developed due to the pulmonary vascular vasoconstruction.
💡
Conclusion & Impact:Liver transplantation can be done successfully to those who responds the vasodilatator therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Portopulmonary hypertension Portopulmonary hypertension is one of the rare pulmonary complications of portal hypertension. Portopulmonary hypertension, is the right ventricular dysfunction caused by increased pulmonary artery pressure which developed due to the pulmonary vascular vasoconstruction. Vasoconstrictors, that cannot be broken-down by the liver and reach to the pulmonary circulation with portosystemic collaterals were blamed for the pathogenesis. First signs were exertional dispnea and fatigue. Patients with symptoms and liver transplantation candidates must be screened for portopulmonary hypertension. Transthoracic echocardiography is used as the screening test. If right ventricular systolic pressure was high at this test, right ventricular catheterization must be done. Specific vasodilatator agents nitric oxide, prostacyslins, endothelin-1 receptor antagonists and phosphodiesterase inhibitors are used for the treatment. Liver transplantation can be done successfully to those who responds the vasodilatator therapy.

Özet

Portopulmoner hipertansiyonPortopulmoner hipertansiyon portal hipertansiyonun seyrek görülen akciğer komplikasyonlarından birisidir. Portopulmoner hipertansiyon pulmoner dolaşımdaki vazokonstriksiyona bağlı pulmoner arter basıncının yükselerek sağ ventrikül işlevlerinin bozulması durumudur. Patogenezinde portosistemik şantlarla akciğer dolaşımına ulaşan, karaciğer tarafından yıkılamayan vazokonstriktörler suçlanmaktadır. Başlangıç belirtisi efor dispnesi ve halsizliktir. Semptomu olan ve karaciğer transplantasyon adayları portopulmoner hipertansiyon açısından taranmalıdır. Tarama testi olarak transtorasik ekokardiyografi kullanılır. Bu testte sağ ventrikül sistolik basıncı yüksek olanlara mutlaka sağ ventrikül kateterizasyonu yapılmadır. Tedavisinde spesifik olarak vazodilatatör olan nitrik oksit, prostasiklinler, endotelin-1 reseptör antagonistleri ve fosfodiesteraz inhibitörleri kullanılmaktadır. Vazodilatatör tedaviye yanıt verenlere karaciğer nakli başarıyla yapılabilmektedir.

🔖

Cite This Article

ALKIM, C. A. (2014). Portopulmonary hypertension. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 48 - Sayı: 4, 257–263. https://ajindex.com/articles/363852

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Machicao VI, Balakrishnan M, Fallon MB. Pulmonary complications in chronic liver disease. Hepatology 2014; 59: 1627-37
  2. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54 (suppl): S43-S54
  3. Mancuso L, Scordato F, Pieri M, Valerio E, Mancuso A. Management of portopulmonary hypertension: New perspectives. World J Gastroenterol 2013; 19: 8252-7
  4. Porres-Aguilar M, Altamirano JT, Torre-Delgadillo A, Charlton MR, Duarte-Rojo A. Portopulmonary hypertension and hepatopulmonary syndrome: clinician-oriented overview. Eur Respir Rev 2012; 21: 223-33
  5. Kawut SM, Krowka MJ, Trotter JF, Roberts KE, Benza RL, Badesh DB et al. Clinical risk factors for portopulmonary hypertension. Hepatology 2008; 48: 196-203
  6. Chen HS, Xing SR, Xu WG, Yang F, Qı XL, Wang LM. et al. Portopulmonary hypertension in cirrhotic patients: Prevalence, clinical features and risk factors. Ex Ther Med 2013; 5: 819-24
  7. Talwalkar JA, Swanson KL, Krowka MJ, Andrews JC, Kamath PS. Prevalence of spontaneous portosystemic shunts in patients with portopulmonary hypertension and effect on treatment. Gastroenterology 2011; 141; 1673-9
  8. Aldenkortt F, Aldenkortt M, Caviezel L, Waeber JL, Weber A, Schiffer E. Portopulmoner hypertension and hepatopulmonary syndrome. World J Gastroenterol 2014; 20: 8072-81
  9. Huffmyer JL, Nemergut ED. Respiratory dysfunction and pulmonary disease in cirrhosis and other hepatic disorders. Respir Care 2007; 52: 1030-6
  10. Safdar Z, Bartolome S, Sussman N. Portopulmonary hypertension: an update. Live Transpl 2012; 18: 881-91
  11. Chen H, Wang F, Xiao J, Qi X, Yang F, Wang L et al. Natural killer cell-mediated immune deficiency or compromise in patients with portopulmonary hypertension. Arch Med Sci 2014; 10: 1055-6
  12. Fritz JS, Fallon MB, Kawut SM. Pulmonary vascular complications of liver disease. Am J Respir Crit Care Med 2013; 187(2): 133-43
  13. Schraufnagel DE, Kay JM. Structural and patologic changes in the lung vasculature in chronic liver disease.Clin Chest Med 1996; 17: 1-15
  14. Moller S, Henriksen JH, Bendtsen F. Extrahepatic complications to cirrhosis and portal hypertension: Haemodynamic and homeostatic aspects. World J Gastroenterol 2014; 20: 15499- 517
  15. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB. Pulmonaryhepatic vascular disorders: a task force report. Eur Respir J 2004; 24: 861-80
  16. Krowka MJ, Weisner RH, Heimbach